These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 22516290)

  • 1. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
    Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
    Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
    Zittema D; Casteleijn NF; Bakker SJ; Boesten LS; Duit AA; Franssen CF; Gaillard CA; Gansevoort RT
    PLoS One; 2017; 12(1):e0169263. PubMed ID: 28081165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
    Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
    Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
    Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
    Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bully renal cysts knock down urine-concentrating capacity in the early rounds.
    Grantham JJ
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):875-7. PubMed ID: 22580782
    [No Abstract]   [Full Text] [Related]  

  • 9. Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
    Malmberg MH; Mose FH; Pedersen EB; Bech JN
    BMC Nephrol; 2020 Aug; 21(1):379. PubMed ID: 32867720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
    Zittema D; van den Berg E; Meijer E; Boertien WE; Muller Kobold AC; Franssen CF; de Jong PE; Bakker SJ; Navis G; Gansevoort RT
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1553-62. PubMed ID: 24993447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
    Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
    Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
    Amro OW; Paulus JK; Noubary F; Perrone RD
    Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on kidney function in subjects exposed to organic solvents. II. The effect of desmopressin in a concentration test and the effect of exposure to organic solvents on renal concentrating ability.
    Askergren A; Allgën LG; Bergström J
    Acta Med Scand; 1981; 209(6):485-8. PubMed ID: 7257866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.
    Blanchard A; Steichen O; De Mota N; Curis E; Gauci C; Frank M; Wuerzner G; Kamenicky P; Passeron A; Azizi M; Llorens-Cortes C
    J Clin Endocrinol Metab; 2013 May; 98(5):2084-9. PubMed ID: 23515451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.
    Graffe CC; Bech JN; Lauridsen TG; Pedersen EB
    Am J Physiol Renal Physiol; 2012 Apr; 302(8):F917-27. PubMed ID: 22262484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
    Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
    Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C
    Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.
    Barash I; Ponda MP; Goldfarb DS; Skolnik EY
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):693-7. PubMed ID: 20167686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.